Search Results - "ROSEN, Oliver" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

by Lin, Nancy U, Prowell, Tatiana, Tan, Antoinette R, Kozak, Marina, Rosen, Oliver, Amiri-Kordestani, Laleh, White, Julia, Sul, Joohee, Perkins, Louise, Beal, Katherine, Gaynor, Richard, Kim, Edward S
Published in Journal of clinical oncology (20.11.2017)

Get full text

Journal Article

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials

by KABBINAVAR, Fairooz F, HURWITZ, Herbert I, JING YI, SARKAR, Somnath, ROSEN, Oliver
Published in Journal of clinical oncology (10.01.2009)

Get full text

Journal Article

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

by BAGRI, Anil, BERRY, Leanne, ROSEN, Oliver, PLOWMAN, Greg D, GUNTER, Bert, SINGH, Mallika, KASMAN, Ian, DAMICO, Lisa A, HONG XIANG, SCHMIDT, Maike, FUH, Germaine, HOLLISTER, Beth
Published in Clinical cancer research (01.08.2010)

Get full text

Journal Article

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

by Cortes, Jorge, Talpaz, Moshe, Smith, Hedy P, Snyder, David S, Khoury, Jean, Bhalla, Kapil N, Pinilla-Ibarz, Javier, Larson, Richard, Mitchell, David, Wise, Scott C, Rutkoski, Thomas J, Smith, Bryan D, Flynn, Daniel L, Kantarjian, Hagop M, Rosen, Oliver, Van Etten, Richard A
Published in Haematologica (Roma) (01.03.2017)

Get full text

Journal Article

Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618

by George, Suzanne, Heinrich, Michael C., Abdul Razak, Albiruni Ryan, Chi, Ping, Gordon, Michael S., Ganjoo, Kristen N., von Mehren, Margaret, Somaiah, Neeta, Trent, Jonathan C., Su, Ying, Ruiz-Soto, Rodrigo, Rosen, Oliver, Janku, Filip
Published in Journal of clinical oncology (20.05.2018)

Get full text

Journal Article

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

by VANHOEFER, Udo, TEWES, Mitra, SEEBER, Siegfried, HARSTRICK, Andreas, BASELGA, José, ROJO, Federico, DIRSCH, Olaf, SCHLEUCHER, Norbert, ROSEN, Oliver, TILLNER, Joachim, KOVAR, Andreas, BRAUN, Ada H, TRARBACH, Tanja
Published in Journal of clinical oncology (01.01.2004)

Get full text

Journal Article

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

by O’Reilly, Eileen M, O’Hara, Mark H, Fisher, George, Wolff, Robert A, Wainberg, Zev A, Ko, Andrew H, Arnott, Jamie, Cabanski, Christopher R, Upadhaya, Samik, Saez-Ibanez, Ana Rosa, Campbell, Jay, Francis, James, Rosen, Oliver, Bucktrout, Samantha, Boffo, Silvia, Dugan, Ute, O’Donnell-Tormey, Jill, Vonderheide, Robert H, Khalil, Danny
Published in Journal for immunotherapy of cancer (01.11.2023)

Get full text

Journal Article

418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A02+ Patients with HPV16+ recurrent, or metastatic solid tumors

418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A02+ Patients with HPV16+ recurrent, or metastatic solid tumors

by Eng, Cathy, Baranda, Joaquina, Taylor, Matthew, Gordon, Michael, Matulonis, Ursula, Janku, Filip, Kornacker, Martin, Kamat, Asha, Rosen, Oliver, Jimeno, Antonio
Published in Journal for immunotherapy of cancer (01.11.2020)

Get full text

Journal Article

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

by Janku, Filip, Abdul Razak, Albiruni R, Chi, Ping, Heinrich, Michael C, von Mehren, Margaret, Jones, Robin L, Ganjoo, Kristen, Trent, Jonathan, Gelderblom, Hans, Somaiah, Neeta, Hu, Simin, Rosen, Oliver, Su, Ying, Ruiz-Soto, Rodrigo, Gordon, Michael, George, Suzanne
Published in Journal of clinical oncology (01.10.2020)

Get full text

Journal Article

3061: Gut microbiome and gene expression changes during a Phase 1 trial of enadenotucirev and radiotherapy

3061: Gut microbiome and gene expression changes during a Phase 1 trial of enadenotucirev and radiotherapy

by Hillson, Lily V., Johnson, Jethro, Ji, Rui Ru, Rosen, Oliver, Qiao, Yu, Ooms, Alex, Maughan, Timothy S., Roxburgh, Campbell S., Hawkins, Maria, O'Cathail, Sean M.
Published in Radiotherapy and oncology (01.05.2024)

Get full text

Journal Article

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K‐ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

by Hurwitz, Herbert I., Yi, Jing, Ince, William, Novotny, William F., Rosen, Oliver
Published in The oncologist (Dayton, Ohio) (01.01.2009)

Get full text

Journal Article

위장관 기질 종양을 치료하는 방법

위장관 기질 종양을 치료하는 방법

by ROSEN OLIVER, SOTO RODRIGO RUIZ, PITMAN JAMA
Year of Publication 12.04.2022

Get full text

Patent

$Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system$

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

by Alexander, Tobias, Thiel, Andreas, Rosen, Oliver, Massenkeil, Gero, Sattler, Arne, Kohler, Siegfried, Mei, Henrik, Radtke, Hartmut, Gromnica-Ihle, Erika, Burmester, Gerd-Rüdiger, Arnold, Renate, Radbruch, Andreas, Hiepe, Falk
Published in Blood (01.01.2009)

Get full text

Journal Article

Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies

Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies

by Hurwitz, Herbert I., Douglas, Pamela S., Middleton, John P., Sledge, George W., Johnson, David H., Reardon, David A., Chen, Dafeng, Rosen, Oliver
Published in The oncologist (Dayton, Ohio) (01.03.2013)

Get full text

Journal Article

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101

by Jimeno, Antonio, Baranda, Joaquina Celebre, Mita, Monica M., Gordon, Michael S., Taylor, Matthew H., Iams, Wade Thomas, Janku, Filip, Matulonis, Ursula A., Bernstein, Howard, Loughhead, Scott, Kornacker, Martin, Zwirtes, Ricardo F., Rosen, Oliver, Eng, Cathy
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

1-[4--5-[1--7--2--12--16--3-]-2-]-3- USE OF 1-[4-BROMO-5-[1-ETHYL-7-METHYLAMINO-2-OXO-12-DIHYDRO-16-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

1-[4--5-[1--7--2--12--16--3-]-2-]-3- USE OF 1-[4-BROMO-5-[1-ETHYL-7-METHYLAMINO-2-OXO-12-DIHYDRO-16-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

by ROSEN OLIVER, FLYNN DANIEL L, SMITH BRYAN D, KAUFMAN MICHAEL D
Year of Publication 31.10.2023

Get full text

Patent

Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)

by Janku, Filip, Heinrich, Michael, Razak, Albiruni, Gordon, Michael, Chi, Ping, Ganjoo, Kristen, Mehren, Margaret von, Somaiah, Neeta, Lee, Jongtae, Kuida, Keisuke, Soto, Rodrigo Ruiz, Rosen, Oliver, George, Suzanne
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

1-[4--5-[1--7--2--12--16--3-]-2-]-3- USE OF 1-[4-BROMO-5-[1-ETHYL-7-METHYLAMINO-2-OXO-12-DIHYDRO-16-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

1-[4--5-[1--7--2--12--16--3-]-2-]-3- USE OF 1-[4-BROMO-5-[1-ETHYL-7-METHYLAMINO-2-OXO-12-DIHYDRO-16-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

by ROSEN OLIVER, FLYNN DANIEL L, SMITH BRYAN D, KAUFMAN MICHAEL D
Year of Publication 24.10.2022

Get full text

Patent

Abstract LB-039: Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor

Abstract LB-039: Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor

by Janku, Filip, Razak, Albi, Gordon, Michael, Brooks, David, Flynn, Daniel, Gupta, Anu, Kaufman, Michael, Leary, Cynthia, Smith, Bryan, Westwood, Deb, Somaiah, Neeta, Helman, Elena, Gerstenberger, Eric, Rosen, Oliver, George, Suzanne
Published in Cancer research (Chicago, Ill.) (01.07.2017)

Get full text

Journal Article

METHODS FOR TREATING CANCERS WITH ACTIVATING ANTIGEN CARRIERS

METHODS FOR TREATING CANCERS WITH ACTIVATING ANTIGEN CARRIERS

by ROSEN, Oliver
Year of Publication 08.11.2023

Get full text

Patent

1
2
3
4
5
6
7
Next
[7]